Clinical Trials Logo
  1. Home
  2. Adenoid Cystic Carcinoma
  3. NCT02942693

Trail Evaluating Particle Therapy With or Without Apatinib for H&N Adenoid Cystic Carcinoma

Adenoid Cystic Carcinoma Clinical Trial

Official title:
A Phase II Randomized Trial of Efficacy and Safety of Particle Therapy With or Without Apatinib as Induction Therapy for Treatment of Head and Neck Adenoid Cystic Carcinoma

Clinical Trial Summary

It is a randomized phase II study to determine the efficacy and safety of particle therapy with or without apatinib as induction therapy for the treatment of head and neck adenoid cystic carcinoma. Participants will be randomized to arm 1: receiving apatinib for 6 weekly followed by particle radiotherapy; arm 2: particle radiotherapy alone.

Clinical Trial Description

The purpose of this study is to determine the efficacy and safety of particle therapy with or without apatinib as induction therapy for the treatment of head and neck adenoid cystic carcinoma. It is a randomized phase II clinical trial with single phase and 2 experimental arms. Participants will be randomized to arm 1, receiving apatinib (0.5g, daily) for 6 weekly followed by particle radiotherapy (proton: 56 GyE/28 Fx, plus carbon: 15 GyE/5 Fx for boost); arm 2: particle radiotherapy alone (proton: 56 GyE/28 Fx, plus carbon: 15 GyE/5 Fx for boost). The short term response will be evaluated using RECIST criteria. And the acute and late toxicities will be evaluated according to NCI CTCAE v4.03. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02942693
Study type Interventional
Source Shanghai Proton and Heavy Ion Center
Contact Lin Kong, MD
Email lin.kong@sphic.org.cn
Status Recruiting
Phase Phase 2
Start date November 2016
Completion date December 2019
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04973683 - AL101 Before Surgery for the Treatment of Notch Activated Adenoid Cystic Cancer Phase 1
Completed NCT01417143 - Dovitinib in Adenoid Cystic Carcinoma Phase 2
Recruiting NCT04140526 - Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC Phase 1/Phase 2
Active, not recruiting NCT05010629 - 9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma Phase 2
Recruiting NCT04801264 - Diagnosis of Adenoid Cystic Carcinoma on 68Ga-PSMA-617 PET-CT and Therapy With 177Lu-EB-PSMA-617 Early Phase 1
Completed NCT03319641 - PSMA-PET Imaging for Advanced ACC/SDC N/A
Completed NCT00581360 - Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid Cystic Carcinoma of the Head and Neck Phase 2
Not yet recruiting NCT05553782 - Drug Screening Using Novel IMD in ACC and Salivary Cancers Early Phase 1
Completed NCT04291300 - Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients Phase 2
Active, not recruiting NCT02775370 - A Study of Apatinib in Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck Phase 2
Active, not recruiting NCT02780310 - Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma Phase 2
Completed NCT04119453 - A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC) Phase 2
Active, not recruiting NCT02098538 - Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma Phase 2
Completed NCT01524692 - Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma Phase 2
Completed NCT01558661 - Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma Phase 2
Recruiting NCT03556228 - Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma Phase 1
Not yet recruiting NCT06462183 - Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC) Phase 1
Recruiting NCT01192087 - Adenoid Cystic Carcinoma, Erbitux, and Particle Therapy Phase 1/Phase 2
Recruiting NCT04209660 - Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers Phase 2
Recruiting NCT05774899 - CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC Phase 1/Phase 2